Prognostic value of the Glasgow prognostic score in colorectal cancer: a meta-analysis of 9,839 patients

• DOI: 10.2147/cmar.s185350
• Publication Date: 2018-12-23T18:23:58Z
• Authors: Xin Lu; Wanying Guo; Wei Xu; Xuelei Zhang; Zhijie Shi; Leizhen Zheng; Wenzhao Zhao
• Keywords: modified Glasgow prognostic score; Neoplasms. Tumors. Oncology. Including cancer and carcinogens; colorectal cancer; Glasgow prognostic score; 3. Good health; meta-analysis; 03 medical and health sciences; 0302 clinical medicine; systematic review; Cancer Management and Research; RC254-282; Original Research

The aim of this study was to perform a systematic review and meta-analysis to evaluate the value of the Glasgow prognostic score (GPS) or modified Glasgow prognostic score (mGPS) in patients with colorectal cancer (CRC).A comprehensive medical literature search was performed using the online databases PubMed, Embase, Web of Science, and the Cochrane Library. After extracting basic characteristics and prognostic data from the included studies, overall survival (OS) and cancer-specific survival (CSS) were pooled as primary outcomes. Subgroup analyses were performed according to therapeutic strategies, models, cutoff values, regions, tumor, node, metastasis stages, sample size, and ages.Forty-three independent cohorts from 41 studies with 9,839 CRC patients were included in the present study. Correlation between GPS or mGPS and OS was analyzed in 32 cohorts of 7,714 patients, and 23 independent cohorts of 5,375 patients focused on the correlation between GPS or mGPS and CSS. The overall outcomes showed that patients with elevated GPS or mGPS were associated with poor OS (HR: 2.20, 95% CI: 1.88-2.57, P<0.001). Elevated GPS or mGPS also resulted in worse CSS (HR: 1.86, 95% CI: 1.59-2.17, P<0.001). The results of the subgroup analyses confirmed the overall outcomes.GPS or mGPS is an accurate prognostic predictor in patients with CRC. Patients with elevated pretreatment GPS or mGPS have a poor prognosis. Subgroup analyses confirmed the overall outcomes. Pretreatment GPS is a useful biomarker in the management of CRC.